Search results
-
ASCO 2025 movers – bispecifics to the rescue
ASCO 2025 movers – bispecifics to the rescue … presented at this year's conference. Winners of ASCO 2025 Company Share price change … use for these bispecific MAbs. Losers of ASCO 2025 Company Share price change …
- 06/05/2025 - 17:48 -
ASCO 2025 – J&J challenges its own multiple myeloma T-cell engagers
ASCO 2025 – J&J challenges its own multiple myeloma T-cell … Note: RP2D=recommended phase 2 dose. Source: ASCO 2025. Conferences Trial …
- 06/05/2025 - 14:10 -
ASCO 2025 – BioNTech shows promise in mesothelioma
ASCO 2025 – BioNTech shows promise in mesothelioma … pts) Note: *investigator-sponsored trial. Source: ASCO 2025. Still, BioNTech's data came from just 31 …
- 06/05/2025 - 17:48 -
ASCO 2025 – an early split between PD-L1 conjugates
ASCO 2025 – an early split between PD-L1 conjugates …
- 06/04/2025 - 17:02 -
ASCO 2025 – Amgen gets one over on Zai Lab
ASCO 2025 – Amgen gets one over on Zai Lab …
- 06/04/2025 - 17:04 -
ASCO 2025 – Astellas's new Claudin18.2 interest
ASCO 2025 – Astellas's new Claudin18.2 interest …
- 06/04/2025 - 17:03 -
ASCO 2025 – Lilly makes a folate foray against Genmab
ASCO 2025 – Lilly makes a folate foray against Genmab … Trial Ph1 Ph1/2 Rainfol-01 Venue ASCO 2025 SGO 2025 Cutoff 9 March 2025 15 … *4mg/kg Q3W dose only; **120mg/m2 Q3W dose only. Source: ASCO 2025. The patients in the LY4170156 trial …
- 06/02/2025 - 19:51 -
ASCO 2025 – BioNTech has a prostate decision to make
ASCO 2025 – BioNTech has a prostate decision to make …
- 06/02/2025 - 19:45 -
ASCO 2025 – J&J takes another prostate cancer shot
ASCO 2025 – J&J takes another prostate cancer shot … 4-8 only; ^^RP2D only; ^^^across whole trial. Source: ASCO 2025, OncologyPipeline & company presentations. …
- 06/02/2025 - 19:45 -
ASCO 2025 – Bicara's ficerafusp claim turns to PD-L1 status
ASCO 2025 – Bicara's ficerafusp claim turns to PD-L1 …
- 06/01/2025 - 21:14
